Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis.

Kumar V, Dong Y, Kumar V, Almawash S, Mahato RI.

Theranostics. 2019 Oct 12;9(25):7537-7555. doi: 10.7150/thno.38913. eCollection 2019.

2.

Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment.

Bariwal J, Kumar V, Chen H, Bhattarai RS, Peng Y, Li W, Mahato RI.

J Control Release. 2019 Sep 10;309:231-243. doi: 10.1016/j.jconrel.2019.07.025. Epub 2019 Jul 19.

PMID:
31330213
3.

Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer.

Yang R, Chen H, Guo D, Dong Y, Miller DD, Li W, Mahato RI.

J Pharmacol Exp Ther. 2019 Sep;370(3):864-875. doi: 10.1124/jpet.119.256628. Epub 2019 Apr 17.

PMID:
30996033
4.

ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer.

Xin X, Lin F, Wang Q, Yin L, Mahato RI.

ACS Appl Mater Interfaces. 2019 Apr 24;11(16):14647-14659. doi: 10.1021/acsami.9b02756. Epub 2019 Apr 12.

5.

Design of Hedgehog pathway inhibitors for cancer treatment.

Bariwal J, Kumar V, Dong Y, Mahato RI.

Med Res Rev. 2019 May;39(3):1137-1204. doi: 10.1002/med.21555. Epub 2018 Nov 28. Review.

6.

Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer.

Lin F, Wen D, Wang X, Mahato RI.

Biomaterials. 2019 Feb;192:95-108. doi: 10.1016/j.biomaterials.2018.10.036. Epub 2018 Nov 3.

PMID:
30447399
7.

Co-delivery of siAlox15 and sunitinib for reversing the new-onset of type 1 diabetes in non-obese diabetic mice.

Peng Y, Wen D, Lin F, Mahato RI.

J Control Release. 2018 Dec 28;292:1-12. doi: 10.1016/j.jconrel.2018.10.032. Epub 2018 Oct 26.

PMID:
30393183
8.

Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus.

Italiya KS, Mazumdar S, Sharma S, Chitkara D, Mahato RI, Mittal A.

Nanomedicine. 2019 Jan;15(1):175-187. doi: 10.1016/j.nano.2018.09.014. Epub 2018 Oct 6.

PMID:
30300750
9.

Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis.

Kumar V, Kumar V, Luo J, Mahato RI.

Mol Ther. 2018 Dec 5;26(12):2798-2811. doi: 10.1016/j.ymthe.2018.08.022. Epub 2018 Sep 1.

10.

Roles of microRNAs in T cell immunity: Implications for strategy development against infectious diseases.

Giri BR, Mahato RI, Cheng G.

Med Res Rev. 2019 Mar;39(2):706-732. doi: 10.1002/med.21539. Epub 2018 Sep 11. Review.

PMID:
30272819
11.

Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis.

Kumar V, Kumar V, Chaudhary AK, Coulter DW, McGuire T, Mahato RI.

Mol Ther Nucleic Acids. 2018 Sep 7;12:490-503. doi: 10.1016/j.omtn.2018.06.004. Epub 2018 Jun 19.

12.

Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice.

Kumar V, Mundra V, Peng Y, Wang Y, Tan C, Mahato RI.

Theranostics. 2018 Jul 5;8(15):4033-4049. doi: 10.7150/thno.24945. eCollection 2018.

13.

Cholesterol and Morpholine Grafted Cationic Amphiphilic Copolymers for miRNA-34a Delivery.

Sharma S, Mazumdar S, Italiya KS, Date T, Mahato RI, Mittal A, Chitkara D.

Mol Pharm. 2018 Jun 4;15(6):2391-2402. doi: 10.1021/acs.molpharmaceut.8b00228. Epub 2018 May 24.

PMID:
29747513
14.

MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis.

Su Q, Kumar V, Sud N, Mahato RI.

Adv Drug Deliv Rev. 2018 Apr;129:54-63. doi: 10.1016/j.addr.2018.01.009. Epub 2018 Jan 31. Review.

PMID:
29391222
15.
16.

Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics.

Date T, Nimbalkar V, Kamat J, Mittal A, Mahato RI, Chitkara D.

J Control Release. 2018 Feb 10;271:60-73. doi: 10.1016/j.jconrel.2017.12.016. Epub 2017 Dec 19. Review.

PMID:
29273320
17.

The fourth annual BRDS on genome editing and silencing for precision medicines.

Chaudhary AK, Bhattarai RS, Mahato RI.

Drug Deliv Transl Res. 2018 Feb;8(1):266-272. doi: 10.1007/s13346-017-0457-5.

18.

Challenges and Recent Advances in Medulloblastoma Therapy.

Kumar V, Kumar V, McGuire T, Coulter DW, Sharp JG, Mahato RI.

Trends Pharmacol Sci. 2017 Dec;38(12):1061-1084. doi: 10.1016/j.tips.2017.09.002. Epub 2017 Oct 20. Review.

PMID:
29061299
19.

EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.

Mondal G, Almawash S, Chaudhary AK, Mahato RI.

Mol Pharm. 2017 Sep 5;14(9):3121-3133. doi: 10.1021/acs.molpharmaceut.7b00355. Epub 2017 Jul 31.

20.

Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.

Chaudhary AK, Mondal G, Kumar V, Kattel K, Mahato RI.

Cancer Lett. 2017 Aug 28;402:1-8. doi: 10.1016/j.canlet.2017.05.007. Epub 2017 May 20.

21.

Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.

Kumar V, Chaudhary AK, Dong Y, Zhong HA, Mondal G, Lin F, Kumar V, Mahato RI.

Sci Rep. 2017 May 10;7(1):1665. doi: 10.1038/s41598-017-01942-7.

22.

Bioconjugate Therapeutics: Current Progress and Future Perspective.

Li F, Mahato RI.

Mol Pharm. 2017 May 1;14(5):1321-1324. doi: 10.1021/acs.molpharmaceut.7b00263. No abstract available.

23.

Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.

Wen D, Peng Y, Lin F, Singh RK, Mahato RI.

Cancer Res. 2017 Jun 15;77(12):3244-3254. doi: 10.1158/0008-5472.CAN-16-2355. Epub 2017 Apr 20.

24.

Recent advances in hepatocellular carcinoma therapy.

Dutta R, Mahato RI.

Pharmacol Ther. 2017 May;173:106-117. doi: 10.1016/j.pharmthera.2017.02.010. Epub 2017 Feb 5. Review.

25.

Nanomedicines for the Treatment of CNS Diseases.

Reynolds JL, Mahato RI.

J Neuroimmune Pharmacol. 2017 Mar;12(1):1-5. doi: 10.1007/s11481-017-9725-x. Epub 2017 Feb 1.

PMID:
28150132
26.

Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma.

Yang R, Mondal G, Ness RA, Arnst K, Mundra V, Miller DD, Li W, Mahato RI.

J Control Release. 2017 Mar 10;249:32-41. doi: 10.1016/j.jconrel.2017.01.028. Epub 2017 Jan 24.

27.

Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice.

Dutta R, Kumar V, Peng Y, Evande RE, Grem JL, Mahato RI.

Pharm Res. 2017 Mar;34(3):564-578. doi: 10.1007/s11095-016-2081-3. Epub 2016 Dec 19.

PMID:
27995525
28.

The third annual BRDS on research and development of nucleic acid-based nanomedicines.

Chaudhary AK, Mahato RI.

Drug Deliv Transl Res. 2017 Feb;7(1):188-193. doi: 10.1007/s13346-016-0345-4.

29.

Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice.

Kattel K, Mondal G, Lin F, Kumar V, Mahato RI.

Mol Pharm. 2017 May 1;14(5):1365-1372. doi: 10.1021/acs.molpharmaceut.6b00929. Epub 2016 Nov 7.

30.

Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer.

Yang R, Mondal G, Wen D, Mahato RI.

Nanomedicine. 2017 Feb;13(2):391-401. doi: 10.1016/j.nano.2016.07.017. Epub 2016 Aug 9.

PMID:
27520724
31.

Mesenchymal stem cell and derived exosome as small RNA carrier and Immunomodulator to improve islet transplantation.

Wen D, Peng Y, Liu D, Weizmann Y, Mahato RI.

J Control Release. 2016 Sep 28;238:166-175. doi: 10.1016/j.jconrel.2016.07.044. Epub 2016 Jul 27.

PMID:
27475298
32.

Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.

Karaca M, Dutta R, Ozsoy Y, Mahato RI.

Mol Pharm. 2016 Jun 6;13(6):1822-32. doi: 10.1021/acs.molpharmaceut.5b00971. Epub 2016 Apr 27.

33.

EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.

Mondal G, Kumar V, Shukla SK, Singh PK, Mahato RI.

Biomacromolecules. 2016 Jan 11;17(1):301-13. doi: 10.1021/acs.biomac.5b01419. Epub 2015 Dec 17.

34.

Synthesis and Characterization of a Novel Mycophenolic Acid-Quinic Acid Conjugate Serving as Immunosuppressant with Decreased Toxicity.

Peng Y, Dong Y, Mahato RI.

Mol Pharm. 2015 Dec 7;12(12):4445-53. doi: 10.1021/acs.molpharmaceut.5b00639. Epub 2015 Nov 11.

PMID:
26529468
35.

Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis.

Kumar V, Mondal G, Dutta R, Mahato RI.

Biomaterials. 2016 Jan;76:144-56. doi: 10.1016/j.biomaterials.2015.10.047. Epub 2015 Oct 23.

PMID:
26524535
36.

Micellar formulation of indocyanine green for phototherapy of melanoma.

Mundra V, Peng Y, Rana S, Natarajan A, Mahato RI.

J Control Release. 2015 Dec 28;220(Pt A):130-140. doi: 10.1016/j.jconrel.2015.10.029. Epub 2015 Oct 19.

PMID:
26482083
37.

Small molecules targeting microRNA for cancer therapy: Promises and obstacles.

Wen D, Danquah M, Chaudhary AK, Mahato RI.

J Control Release. 2015 Dec 10;219:237-247. doi: 10.1016/j.jconrel.2015.08.011. Epub 2015 Aug 6. Review.

38.

Nanoparticle-mediated drug delivery for treating melanoma.

Mundra V, Li W, Mahato RI.

Nanomedicine (Lond). 2015;10(16):2613-33. doi: 10.2217/nnm.15.111. Epub 2015 Aug 5. Review.

39.

Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma.

Mundra V, Peng Y, Kumar V, Li W, Miller DD, Mahato RI.

Drug Deliv Transl Res. 2015 Jun;5(3):199-208. doi: 10.1007/s13346-015-0226-2.

40.

Core-shell nanoparticulate formulation of gemcitabine: lyophilization, stability studies, and in vivo evaluation.

Chitkara D, Mittal A, Mahato RI, Kumar N.

Drug Deliv Transl Res. 2014 Dec;4(5-6):439-51. doi: 10.1007/s13346-014-0206-y.

PMID:
25787206
41.

Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer.

Kattel K, Evande R, Tan C, Mondal G, Grem JL, Mahato RI.

Br J Clin Pharmacol. 2015 Aug;80(2):267-75. doi: 10.1111/bcp.12620. Epub 2015 Jun 11.

42.

Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer.

Kumar V, Mondal G, Slavik P, Rachagani S, Batra SK, Mahato RI.

Mol Pharm. 2015 Apr 6;12(4):1289-98. doi: 10.1021/mp500847s. Epub 2015 Feb 25.

43.

miRNAs as targets for cancer treatment: therapeutics design and delivery. Preface.

Li F, Mahato RI.

Adv Drug Deliv Rev. 2015 Jan;81:v-vi. doi: 10.1016/j.addr.2014.11.005. Epub 2014 Dec 9. No abstract available.

44.

miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies.

Chitkara D, Mittal A, Mahato RI.

Adv Drug Deliv Rev. 2015 Jan;81:34-52. doi: 10.1016/j.addr.2014.09.006. Epub 2014 Sep 22. Review.

PMID:
25252098
45.

Delivery and targeting of miRNAs for treating liver fibrosis.

Kumar V, Mahato RI.

Pharm Res. 2015 Feb;32(2):341-61. doi: 10.1007/s11095-014-1497-x. Epub 2014 Sep 4. Review.

PMID:
25186440
46.

A preface for engineered biomimetic tissue platforms for in vitro drug evaluation.

Wang DA, Mahato RI.

Mol Pharm. 2014 Jul 7;11(7):1931-2. doi: 10.1021/mp500349x. No abstract available.

PMID:
24998338
47.

Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.

Mittal A, Chitkara D, Behrman SW, Mahato RI.

Biomaterials. 2014 Aug;35(25):7077-87. doi: 10.1016/j.biomaterials.2014.04.053. Epub 2014 May 14.

PMID:
24836307
48.

LHRH-conjugated micelles for targeted delivery of antiandrogen to treat advanced prostate cancer.

Wen D, Chitkara D, Wu H, Danquah M, Patil R, Miller DD, Mahato RI.

Pharm Res. 2014 Oct;31(10):2784-95. doi: 10.1007/s11095-014-1375-6. Epub 2014 May 2.

PMID:
24789451
49.

MicroRNAs and drug resistance in prostate cancers.

Li F, Mahato RI.

Mol Pharm. 2014 Aug 4;11(8):2539-52. doi: 10.1021/mp500099g. Epub 2014 Apr 29. Review.

50.

Mesenchymal stem cell-based therapy for type 1 diabetes.

Wu H, Mahato RI.

Discov Med. 2014 Mar;17(93):139-43. Review.

Supplemental Content

Loading ...
Support Center